Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-102 phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics study in healthy participants
NL-OMON60952Phase 1Completed
- Sponsor
- Arvinas
- Start
- Jan 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of ARV-102 in Parkinson's disease (PD), sponsored by Arvinas. Primary endpoint: Primary endpoint(s). Started Jan 2024; status: completed.
02
Drugs
ARV-102
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON60952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60952.